Skip to main navigation Skip to search Skip to main content

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

  • PanACEA consortium
  • Ludwig Maximilian University of Munich
  • University of St Andrews
  • TASK Applied Science
  • University of Cape Town
  • University of the Witwatersrand
  • Swiss Tropical and Public Health Institute
  • Kilimanjaro Clinical Research Institute, Moshi, Tanzania
  • NIMR-Mbeya Medical Research Center, Mbeya, Tanzania
  • University Teaching Hospital Lusaka
  • Makerere University
  • Centre de Recherches Médicales de Lambaréné
  • University of Tübingen
  • Kenya Medical Research Institute
  • University College London
  • Amsterdam UMC
  • Radboud University Medical Center

Research output: Contribution to journalArticleAcademicpeer-review

13 Downloads (Pure)

Abstract

Introduction: The Pan-African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA) was designed to build tuberculosis (TB) trial capacity whilst conducting clinical trials on novel and existing agents to shorten and simplify TB treatment. PanACEA has now established a dynamic network of 11 sub-Saharan clinical trial sites and four European research institutions. Objectives: In 2011, a capacity development program, funded by the European & Developing Countries Clinical Trials Partnership (EDCTP), was launched with four objectives, aiming at strengthening collaborating TB research sites to reach the ultimate goal of becoming self-sustainable institutions: networking; training; conducting clinical trials; and infrastructure scaling-up of sites. Methods: Assessment in six sub-Saharan TB-endemic countries (Gabon, Kenya, South Africa, Tanzania, Uganda and Zambia) were performed through a structured questionnaire, site visits, discussion with the PanACEA consortium, setting of milestones and identification of priorities and followed-up with evaluations of each site. The results of this needs-based assessment was then translated into capacity development measures. Results: In the initial phase, over a four-year period (March 2011 – June 2014), the programme scaled-up six sites; conducted a monitoring training program for 11 participants; funded five MSc and four PhD students, fostering gender balance; conducted four epidemiological studies; supported sites to conduct five Phase II studies and formed a sustainable platform for TB research (panacea-tb.net). Conclusion: Our experience of conducting TB clinical trials within the PanACEA programme environment of mentoring, networking and training has provided a sound platform for establishing future sustainable research centres. Our goal of facilitating emergent clinical TB trial sites to better initiate and lead research activities has been mostly successful.
Original languageEnglish
Article number106776
JournalActa tropica
Volume238
DOIs
Publication statusPublished - 1 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 4 - Quality Education
    SDG 4 Quality Education
  3. SDG 9 - Industry, Innovation, and Infrastructure
    SDG 9 Industry, Innovation, and Infrastructure

Keywords

  • Capacity development
  • Infrastructure upgrade
  • Networking
  • Sub-Saharan Africa
  • Sustainability
  • Training

Fingerprint

Dive into the research topics of 'Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach'. Together they form a unique fingerprint.

Cite this